Efgartigimod
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 404 publications
Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 17, 2026
Efgartigimod as a Steroid-sparing Therapy for Evans Syndrome: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: June 10, 2026
The Clinical Efficacy and Safety of Efgartigimod in the Treatment of Autoimmune Encephalitis.
Journal: Immunological investigations
Published: May 20, 2026
Real-world implications of efgartigimod in managing refractory myasthenia gravis.
Journal: Expert opinion on biological therapy
Published: May 20, 2026
Evaluating nipocalimab for the treatment of chronic inflammatory demyelinating polyneuropathy.
Journal: Expert review of neurotherapeutics
Published: May 19, 2026
Nipocalimab (Imaavy) for myasthenia gravis.
Journal: The Medical letter on drugs and therapeutics
Published: May 15, 2026
Corrigendum to 'Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20' [Journal of the Neurological Sciences, 486 (2026) 125918].
Journal: Journal of the neurological sciences
Published: May 13, 2026
Correspondence regarding: Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin.
Journal: Clinical neurology and neurosurgery
Published: April 30, 2026
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches.
Journal: Brain and behavior
Published: April 30, 2026
Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report.
Journal: Frontiers in immunology
Published: April 24, 2026
Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review.
Journal: The American journal of case reports
Published: April 16, 2026
Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade.
Journal: Frontiers in immunology
Published: April 13, 2026
Last Updated: 06/30/2026